TMCnet - World's Largest Communications and Technology Community



Research and Markets: PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022
[February 28, 2014]

Research and Markets: PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022" report to their offering.

HCV Market Is Expected to Grow During the Forecast Period

The HCV market generated approximately $4.0 billion from global sales in 2012. Over the next 10 years, this market is expected to grow to reach $10.8 billion, with major growth occurring in the main HCV markets, such as the US.

Some of the main drivers of growth are expected to be:

- Introduction of interferon-free HCV regimens, which have an improved side effect profile compared with current HCV therapies

- Increase in patient awareness of HCV through screening initiatives and public awareness campaigns

- A paradigm shift toward preventive care of HCV in most countries

The barriers limiting the growth of the market include:

- Limited patient awareness regarding the threat of HCV

- Concerns over decreasing healthcare costs as part of government austerity measures

Pharma Giants Battle as New Entrants Leverage Next-Generation HCV Regimens to Capture Market Share

Roche and Merck have been the HCV market leaders for the better part of two decades. The companies leveraged their interferon and ribavirin drugs to quickly capture market share. Roche's and Merck's commitment to innovation resulted in the launch of peginterferon HCV therapies, which quickly overtook the market, but bothcompanies fell behind in the race to develop direct-acting antiviral (DAA) therapies for HCV.

This enabled Vertex (News - Alert) to establish itself as the leader in the US through with the launch of Incivek (telaprevir). Janssen was also able to capitalize on the demand for DAAs to become the front-runner in many European markets through the launch of Incivo (telaprevir).

The authors anticipates that the launch of next-generation HCV regimens will continue to enable new entrants, such as Gilead, AbbVie, Bristol-Myers Squibb, and Boehringer Ingelheim, to capture market share. Companies with interferon-free regimens are expected to quickly capture market share in the US, Japan, and many European countries.

New Entrants Welcomed in the Market after the Launch of Next-Generation HCV Regimens

There will still be demand for improved HCV therapies even after next-generation HCV therapies have overtaken the market. Most late-stage HCV regimens are focused on treating HCV genotype 1 infection since it is the most prevalent strain, but there is demand for therapies with pan-genotypic activity. A regimen that is well tolerated, effective against all HCV genotypes, and requires less than 12 weeks of therapy will likely steal patient share from the next-generation HCV therapies that are included in this forecast.

Launch of Interferon-Free Regimens Will Fundamentally Change the HCV Treatment Algorithm in the US, Japan, and Many European Countries

AbbVie's combination therapy (ABT-450, ABT-333, and ABT-267) is expected to be among the first interferon-free HCV regimens to launch in several countries. The regimen's tolerability, efficacy in both treatment-naïve and treatment-experienced patients, and short duration of therapy are expected to result in it becoming a front-line therapy. The authors forecasts peak year sales for the regimen of $3.1 billion in 2018.

Gilead's fixed-dose, single-pill HCV regimen, sofosbuvir/ledipasvir, is forecast to launch in most countries shortly after the first of the interferon-free therapies. The ability of the sofosbuvir/ledipasvir regimen to be safe and effective without co-administration with ribavirin is expected to result in the drug becoming the standard of care in many markets. The authors anticipates peak year sales for sofosbuvir/ledipasvir of $4.3 billion in 2019.

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Competitive Assessment

7 Opportunity and Unmet Need

8 Pipeline Assessment

9 Current and Future Players

10 Market Outlook

11 Appendix

Companies Mentioned

  • AbbVie
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Gilead
  • Janssen
  • Merck
  • Roche
  • Vertex

For more information visit

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy